In 2008, Takeda made waves in the biotech world when it agreed to pay $8.8 billion for Millennium Pharmaceuticals, a trailblazing outfit from Cambridge, MA. Now, years into integrating its acquisition, Takeda is dropping the Millennium moniker, spelling the end of the line for what was once an iconic brand in biotech. Once billed as Millennium: The Takeda Oncology Company, the Japanese drugmaker's cancer business will from now on be called simply Takeda Oncology. More